Low temperature synthesis of multiwalled carbon nanotubes and incorporation into an organic solar cell

Abstract: Metal nanoparticle (MNP) catalysts used for the synthesis of multiwalled carbon nanotubes (MWCNTs) consisted of single metals (Fe, Ni or Co) and bimetallic mixture (CoFe, NiFe or NiCo). MWCNTs were successfully synthesised at 200 _C in 10 min using liquefied petroleum gas as carbon source with non-equilibrium plasma enhanced chemical vapour deposition (PECVD) method. The nanostructures and the morphology of the MNPs and the MWCNTs film were characterised using relevant microscopic and spectroscopic methods. The synthesised MWCNTs were used as part of the electrode material in organic solar cell (OSC) set-up. Poly (3,4- ethylenedioxythiophene): polystyrene sulfonate (PEDOT: PSS) was used as an electron transporter and poly-3-hexyl thiophene (P3HT) as an electron donor. The performance of OSC devices was tested using standard electrical measurements and solar simulator operating at 100 mW/cm2. The measured power conversion efficiencies was found to be dependent on the metal catalyst used during synthesis. Among all the catalysts employed in this investigation, the best device performance was found from the synthesis of MWCNTs using Fe as a catalyst followed by Co and then Ni, respectively

Evidence for Anisotropic Vortex Dynamics and Pauli Limitation in the Upper Critical Field of FeSe1-xTex

We have determined HC2(T) for FeSe1-xTex (x=0.52) single crystals using resistivity measurements at high static and pulsed magnetic field, as well as specific heat measurements up to 9T. We find that the significant anisotropy of the initial slope of HC2(T) determined from resistivity measurements, is not present when HC2 is determined from the specific heat results. This suggests that the thermodynamic upper critical field is almost isotropic, and that anisotropic vortex dynamics play a role. Further evidence of anisotropic vortex dynamics is found in the behaviour in pulsed field. We also find that Pauli limiting must be included in order to fit the temperature dependence of HC2, indicating probably higher effective mass in FeSe1-xTex than in other Fe superconductors

Quantum dynamics of crystals of molecular nanomagnets inside a resonant cavity

It is shown that crystals of molecular nanomagnets exhibit enhanced magnetic relaxation when placed inside a resonant cavity. Strong dependence of the magnetization curve on the geometry of the cavity has been observed, providing evidence of the coherent microwave radiation by the crystals. A similar dependence has been found for a crystal placed between Fabry-Perot superconducting mirrors. These observations open the possibility of building a nanomagnetic microwave laser pumped by the magnetic field

The role of solvent additive in metal nano-composite doped thin film organic solar cell

In this study, organic solar cells (OSCs) were designed using the solution processing method based on spin coating. The influence of solvent additive (1-chloronapthalene (CN)) and cadmium doped barium nitrate nanoparticle incorporated into the photoactive medium based on poly(3-hexylthiophene-2,5- diyl (P3HT): [6,6]-phenyl-C61-butyric acid methyl ester (PCBM) was investigated. The power conversion efficiency of the pristine device was compared to the power conversion efficiency of the devices fabricated with 30v% of 1- chloronapthalene and different weight concentrations of nanoparticles. An optimum efficiency of 3.55 % was attained at 0.3 wt.% with solvent additive compared to 3.25 % obtained for the pristine device. This increase is attributed to a rise in charge transport of 5.32 × 10-2 cm2V-1s-1. Further investigation on the morphological properties of the nanoparticles reveals the crystalline nature of the nanoparticle

Suppression of superconductivity by non-magnetic disorder in organic superconductor κ\kappa-(BEDT-TTF)2_{2}Cu(NCS)2_{2}

The suppression of superconductivity by nonmagnetic disorder is investigated systematically in the organic superconductor $\kappa$-(BEDT-TTF)$_2$Cu(NCS)$_2$. We introduce a nonmagnetic disorder arising from molecule substitution in part with deuterated BEDT-TTF or BMDT-TTF for BEDT-TTF molecules and molecular defects introduced by X-ray irradiation. A quantitative evaluation of the scattering time $\tau_{\rm dHvA}$ is carried out by de Haas-van Alphen (dHvA) effect measurement. A large reduction in $T_{\rm c}$ with a linear dependence on $1/\tau_{\rm dHvA}$ is found in the small-disorder region below $1/\tau_{\rm dHvA} \simeq$ 1 $\times$ 10$^{12}$ s$^{-1}$ in both the BMDT-TTF molecule-substituted and X-ray-irradiated samples. The observed linear relation between $T_{\rm c}$ and $1/\tau_{\rm dHvA}$ is in agreement with the Abrikosov-Gorkov (AG) formula, at least in the small-disorder region. This observation is reasonably consistent with the unconventional superconductivity proposed thus far for the present organic superconductor. A deviation from the AG formula, however, is observed in the large-disorder region above $1/\tau_{\rm dHvA} \simeq$ 1 $\times$ 10$^{12}$ s$^{-1}$, which reproduces the previous transport study (J. G. Analytis {\it et al.}: Phys. Rev. Lett. {\bf 96} (2006) 177002). We present some interpretations of this deviation from the viewpoints of superconductivity and the inherent difficulties in the evaluation of scattering time.Comment: 11 pages, 6 figure

Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative

Objective: A patient-derived composite measure of the impact of rheumatoid arthritis (RA), the rheumatoid arthritis impact of disease (RAID) score, takes into account pain, functional capacity, fatigue, physical and emotional wellbeing, quality of sleep and coping. The objectives were to finalise the RAID and examine its psychometric properties. Methods: An international multicentre cross-sectional and longitudinal study of consecutive RA patients from 12 European countries was conducted to examine the psychometric properties of the different combinations of instruments that might be included within the RAID combinations scale (numeric rating scales (NRS) or various questionnaires). Construct validity was assessed cross-sectionally by Spearman correlation, reliability by intraclass correlation coefficient (ICC) in 50 stable patients, and sensitivity to change by standardised response means (SRM) in 88 patients whose treatment was intensified. Results: 570 patients (79% women, mean±SD age 56±13 years, disease duration 12.5±10.3 years, disease activity score (DAS28) 4.1±1.6) participated in the validation study. NRS questions performed as well as longer combinations of questionnaires: the final RAID score is composed of seven NRS questions. The final RAID correlated strongly with patient global (R=0.76) and significantly also with other outcomes (DAS28 R=0.69, short form 36 physical −0.59 and mental −0.55, p<0.0001 for all). Reliability was high (ICC 0.90; 95% CI 0.84 to 0.94) and sensitivity to change was good (SRM 0.98 (0.96 to 1.00) compared with DAS28 SRM 1.06 (1.01 to 1.11)). Conclusion: The RAID score is a patient-derived composite score assessing the seven most important domains of impact of RA. This score is now validated; sensitivity to change should be further examined in larger studies

Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study

Objective: To assess the 1-year efficacy and safety of a regimen of tocilizumab plus methotrexate or placebo, which was augmented by a treat-to-target strategy from week 24. Methods: ACT-RAY was a double-blind, 3-year trial. Adults with active rheumatoid arthritis despite methotrexate were randomised to add tocilizumab to ongoing methotrexate (add-on strategy) or to switch to tocilizumab plus placebo (switch strategy). Tocilizumab 8 mg/kg was administered every 4 weeks. Conventional open-label disease-modifying antirheumatic drugs (DMARDs) other than methotrexate were added at week 24 or later in patients with DAS28>3.2. Results: 556 patients were randomised; 85% completed 52 weeks. The proportion of patients receiving open-label DMARDs was comparable in the add-on (29%) and switch (33%) arms. Overall, week 24 results were maintained or further improved at week 52 in both arms. Some endpoints favoured the add-on strategy. Mean changes in Genant-modified Sharp scores were small; more add-on (92.8%) than switch patients (86.1%) had no radiographic progression. At week 52, comparable numbers of patients had antidrug antibodies (ADAs; 1.5% and 2.2% of add-on and switch patients, respectively) and neutralising ADAs (0.7% and 1.8%). Rates of serious adverse events and serious infections per 100 patient-year (PY) were 11.3 and 4.5 in add-on and 16.8 and 5.5 in switch patients. In patients with normal baseline values, alanine aminotransferase elevations >3× upper limit of normal were observed in 11% of add-on and 3% of switch patients. Conclusions: Despite a trend favouring the add-on strategy, these data suggest that both tocilizumab add-on and switch strategies led to meaningful clinical and radiographic responses

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

Objective: In patients with active rheumatoid arthritis (RA) despite methotrexate, to compare the efficacy of adding tocilizumab to that of switching to tocilizumab monotherapy. Methods: Double-blind, 2-year study in which adults with active RA (DAS28 >4.4) despite methotrexate were randomly assigned either to continue methotrexate with the addition of tocilizumab (MTX+TCZ) 8 mg/kg every 4 weeks or switch to tocilizumab and placebo (TCZ+PBO). The primary endpoint was the DAS28–erythrocyte sedimentation rate (ESR) remission rate at week 24. Secondary objectives included other symptomatic outcomes, quality of life and progression of structural damage. Results: Of 556 randomly assigned patients, 512 (92%) completed 24 weeks. DAS28–ESR remission rates were 40.4% for TCZ+MTX and 34.8% for TCZ+PBO (p=0.19); American College of Rheumatology 20/50/70/90 rates were 71.5%/45.5%/24.5%/5.8% (TCZ+MTX) and 70.3%/40.2%/25.4%/5.1% (TCZ+PBO; differences not significant). A significant difference between groups was seen for low DAS28 (61.7% vs 51.4%). Radiographic progression was small and not different between groups (Genant–Sharp score progression ≤ smallest detectable change in 91% (TCZ+MTX) and 87% (TCZ+PBO)). Rates per 100 patient-years of serious adverse events and serious infections were 21 and six, respectively, for TCZ+MTX and 18 and six, respectively, for TCZ+PBO. Alanine aminotransferase elevations greater than threefold the upper limit of normal occurred in 7.8% and 1.2% of TCZ+MTX and TCZ+PBO patients, respectively. Conclusion: No clinically relevant superiority of the TCZ+MTX add-on strategy over the switch to tocilizumab monotherapy strategy was observed. The combination was more commonly associated with transaminase increases. Meaningful clinical and radiographic responses were achieved with both strategies, suggesting that tocilizumab monotherapy might be a valuable treatment strategy in suitable RA patients